Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.
Sumitomo Pharma reported strong earnings momentum for the third quarter of the fiscal year ending March 31, 2026, with revenue rising to ¥347.7 billion from ¥293.2 billion year-on-year and core operating profit surging more than fourfold to ¥109.4 billion, driven by higher sales, lower selling, general and administrative expenses, and reduced R&D spending. Operating profit jumped to ¥109.8 billion and net profit attributable to owners of the parent climbed to ¥107.7 billion, pushing ROE to 43.0% and ROIC to 20.7%, although cash and cash equivalents declined to ¥57.3 billion amid lower operating cash flow in the prior year and reduced investing inflows, highlighting a trade-off between improved profitability and a tighter liquidity position as the company advances its pipeline and adjusts its cost structure.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2501.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. (Securities Code: 4506) is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sale of prescription drugs, with a focus on innovative therapies under IFRS reporting standards and a global market presence.
Average Trading Volume: 10,215,052
Technical Sentiment Signal: Buy
Current Market Cap: Yen899.1B
See more data about 4506 stock on TipRanks’ Stock Analysis page.